Xenon Pharmaceuticals Q2 2026 Earnings Report

Xenon Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.16
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Xenon Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.67 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Xenon Pharmaceuticals Announcement Details

• Quarter: Q2 2026
• Date: 8/10/2026
• Time: After Market Closes
• Conference Call Date: Monday, August 10, 2026
• Conference Call Time: 4:30PM ET

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs. Its lead asset, XEN1101, is an orally administered potassium channel opener being evaluated for the treatment of focal epilepsy, while other programs target sodium and calcium channel modulators for migraine prophylaxis and pain management. Xenon has established strategic collaborations with academic institutions and contract research organizations to conduct global Phase 1 and Phase 2 studies, with trial sites spanning North America and Europe. Throughout its development efforts, the company leverages translational biomarkers and electrophysiology to guide clinical dosing and patient selection.

Founded in 1999 and headquartered in Burnaby, British Columbia, Xenon Pharmaceuticals trades on the Nasdaq under the ticker XENE. Over its history, the company has transitioned from a technology licensee to a fully integrated drug developer, expanding its team of medicinal chemists, pharmacologists and clinical specialists. Xenon is led by President and Chief Executive Officer C. Scott Myers, whose experience in neuroscience drug development supports the company’s mission to advance therapies for patients with unmet medical needs worldwide.